Tumor antigen acrosin binding protein normalizes mitotic spindle function to promote cancer cell proliferation

Cancer Research

Volumn 70, Issue 19, 2010, Pages 7652-7661

  Whitehurst, Angelique W ^a   Xie, Yang ^b   Purinton, Scott C ^c   Cappell, Kathryn M ^a   Swanik, Jackie T ^a   Larson, Brittany ^a   Girard, Luc ^b   Schorge, John O ^d   White, Michael A ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACROSIN BINDING PROTEIN; BINDING PROTEIN; NUCLEAR MITOTIC APPARATUS PROTEIN; NUCLEAR PROTEIN; PACLITAXEL; SMALL INTERFERING RNA; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER RELAPSE; CANCER RESISTANCE; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; DISEASE FREE SURVIVAL; DNA SYNTHESIS; DRUG SENSITIVITY; EXPLANT; GENETIC SCREENING; HUMAN; HUMAN CELL; MITOSIS; MITOSIS SPINDLE; OVARY CANCER; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SURVIVAL TIME;

ANTIGENS, NUCLEAR; CARRIER PROTEINS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MITOSIS; MITOTIC SPINDLE APPARATUS; NUCLEAR MATRIX-ASSOCIATED PROTEINS; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 77957336317     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0840     Document Type: Article

References (36)

1. Rieder CL, Maiato H. Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. Dev Cell 2004;7:637-51.
2. Gascoigne KE, Taylor SS. How do anti-mitotic drugs kill cancer cells? J Cell Sci 2009;122:2579-85.
3. Zalcberg J, Millward M, Bishop J, et al. Phase II study of docetaxel and cisplatin in advanced non-small cell lung cancer. J Clin Oncol 1998;16:1948-53.
4. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002;346:92-8.
5. Ichiki M, Kawasaki M, Takayama K, et al. A multicenter phase II study of carboplatin and paclitaxel with a biweekly schedule in patients with advanced non-small cell lung cancer: Kyushu thoracic oncology group trial. Cancer Chemother Pharmacol 2006;58:368-73.
6. Yumuk PF, Turhal NS, Gumus M, et al. Results of paclitaxel (day 1 and 8) and carboplatin given on every three weeks in advanced (stage III-IV) non-small cell lung cancer. BMC Cancer 2005;5:10.
7. Ramaswamy S. Rational design of cancer-drug combinations. N Engl J Med 2007;357:299-300.
8. Whitehurst AW, Bodemann BO, Cardenas J, et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 2007;446:815-9.
9. Simpson A, Caballero OL, Jungbluth A, Chen Y-T, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005;5:615-25.
10. Okumura H, Noguchi Y, Uenaka A, et al. Identification of an HLA-A24-restricted OY-TES-1 epitope recognized by cytotoxic T-cells. Microbiol Immunol 2005;49:1009-16.
11. Ono T, Kurashige T, Harada N, et al. Identification of proacrosin binding protein sp32 precursor as a human cancer/testis antigen. Proc Natl Acad Sci U S A 2001;98:3282-7.
12. Tammela J, Uenaka A, Ono T, et al. OY-TES-1 expression and serum immunoreactivity in epithelial ovarian cancer. Int J Oncol 2006;29:903-10.
13. Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun 2004;4:1.
14. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of affymetrix GeneChip probe level data. Nucleic Acids Res 2003;31:e15.
15. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-64.
16. Yeung KY, Fraley C, Murua A, Raftery AE, Ruzzo WL. Model-based clustering and data transformations for gene expression data. Bioinformatics 2001;17:977-87.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
18. Collett D. Modelling survival data in medical research. Chapman & Hall/CRC; 2003.
19. Langdon SP, Lawrie SS, Hay FG, et al. Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Res 1988;48:6166-72.
20. Ban KH, Torres JZ, Miller JJ, et al. The END network couples spindle pole assembly to inhibition of the anaphase-promoting complex/cyclosome in early mitosis. Dev Cell 2007;13:29-42.
21. Quintyne NJ, Reing JE, Hoffelder DR, Gollin SM, Saunders WS. Spindle multipolarity is prevented by centrosomal clustering. Science 2005;307:127-9.
22. Kremer BE, Haystead T, Macara IG. Mammalian septins regulate microtubule stability through interaction with the microtubule-binding protein MAP4. Mol Biol Cell 2005;16:4648-59.
23. Tirnauer JS, Bierer BE. EB1 proteins regulate microtubule dynamics, cell polarity, and chromosome stability. J Cell Biol 2000;149:761-6.
24. Compton DA, Luo C. Mutation of the predicted p34cdc2 phosphorylation sites in NuMA impair the assembly of the mitotic spindle and block mitosis. J Cell Sci 1995;108:621-33.
25. Gaglio T, Saredi A, Compton DA. NuMA is required for the organization of microtubules into aster-like mitotic arrays. J Cell Biol 1995;131:693-708.
26. Merdes A, Heald R, Samejima K, Earnshaw WC, Cleveland DW. Formation of spindle poles by dynein/dynactin-dependent transport of NuMA. J Cell Biol 2000;149:851-62.
27. Merdes A, Ramyar K, Vechio JD, Cleveland DW. A complex of NuMA and cytoplasmic dynein is essential for mitotic spindle assembly. Cell 1996;87:447-58.
28. Silkworth WT, Nardi IK, Scholl LM, Cimini D. Multipolar spindle pole coalescence is amajor source of kinetochore mis-attachment and chromosome mis-segregation in cancer cells. PLoS ONE 2009;4:e6564.
29. Ganem NJ, Godinho SA, Pellman D. A mechanism linking extra centrosomes to chromosomal instability. Nature 2009;460:278-82.
30. Bast RC, Jr., Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 2009;9:415-28.
31. Weaver BA, Bonday ZQ, Putkey FR, Kops GJ, Silk AD, Cleveland DW. Centromere-associated protein-E is essential for the mammalian mitotic checkpoint to prevent aneuploidy due to single chromosome loss. J Cell Biol 2003;162:551-63.
32. Weaver BA, Silk AD, Montagna C, Verdier-Pinard P, Cleveland DW. Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer Cell 2007;11:25-36.
33. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998;396:643-9.
34. Baker DJ, Jin F, Jeganathan KB, van Deursen JM. Whole chromosome instability caused by Bub1 insufficiency drives tumorigenesis through tumor suppressor gene loss of heterozygosity. Cancer Cell 2009;16:475-86.
35. Kwon M, Godinho SA, Chandhok NS, et al. Mechanisms to suppress multipolar divisions in cancer cells with extra centrosomes. Genes Dev 2008;22:2189-203.
36. Rancati G, Pavelka N, Fleharty B, et al. Aneuploidy underlies rapid adaptive evolution of yeast cells deprived of a conserved cytokinesis motor. Cell 2008;135:879-93.